Drugmakers and industry groups are calling for changes to the US Food and Drug Administration’s (FDA) draft guidance on bioavailability (BA) studies submitted as part of an investigational new drug (IND) application or new drug application (NDA).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,